{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:36:08Z","timestamp":1792701368712,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["765"],"award-info":[{"award-number":["765"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vph.2025.107548","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:45:30Z","timestamp":1759301130000},"page":"107548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Apelin in glioblastoma: A dual target for tumor and vascular intervention"],"prefix":"10.1016","volume":"161","author":[{"given":"Gabriela E.","family":"Wachholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan W.","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.vph.2025.107548_bb0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/jpm11040258","article-title":"Diagnosis and management of Glioblastoma: a comprehensive perspective","volume":"11","author":"Gilard","year":"2021","journal-title":"J. Pers. Med."},{"issue":"7","key":"10.1016\/j.vph.2025.107548_bb0015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"Suppl. 5","key":"10.1016\/j.vph.2025.107548_bb0020","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009","volume":"14 Suppl 5","author":"Dolecek","year":"2012","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.vph.2025.107548_bb0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","author":"DeCordova","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A review of glioblastoma immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neuro-Oncol."},{"issue":"8","key":"10.1016\/j.vph.2025.107548_bb0035","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.3390\/ijms24087047","article-title":"Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets","volume":"24","author":"Erices","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.vph.2025.107548_bb0040","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.vph.2025.107548_bb0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/08830185.2022.2101647","article-title":"Combinatorial approaches to effective therapy in glioblastoma (GBM): current status and what the future holds","volume":"41","author":"Asija","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.vph.2025.107548_bb0050","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.vph.2025.107548_bb0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Mason WP; trial investigators. Short-course radiation plus Temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.vph.2025.107548_bb0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.vph.2025.107548_bb0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1017\/S0317167100012166","article-title":"Glioblastoma: patterns of recurrence and efficacy of salvage treatments","volume":"38","author":"Oh","year":"2011","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.vph.2025.107548_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"21","key":"10.1016\/j.vph.2025.107548_bb0075","first-page":"6480","article-title":"Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.vph.2025.107548_bb0080","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajpath.2012.06.030","article-title":"Mechanisms of glioma-associated neovascularization","volume":"181","author":"Hardee","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.vph.2025.107548_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"issue":"5","key":"10.1016\/j.vph.2025.107548_bb0090","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor development and angiogenesis in adult brain tumor: glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.vph.2025.107548_bb0095","first-page":"1111","article-title":"Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors","volume":"56","author":"Griffioen","year":"1996","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","article-title":"Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium","volume":"88","author":"Griffioen","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L","article-title":"Angiogenesis inhibitors overcome tumor induced endothelial cell anergy","volume":"80","author":"Griffioen","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.vph.2025.107548_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1096\/fj.05-4493com","article-title":"Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors","volume":"20","author":"Dirkx","year":"2006","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"issue":"10","key":"10.1016\/j.vph.2025.107548_bb0120","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1158\/1078-0432.CCR-10-2443","article-title":"Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer","volume":"17","author":"Dings","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"van Beijnum","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.vph.2025.107548_bb0135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/NEN.0b013e3181a2b8F4-9","article-title":"Dephosphorylation of beta-arrestin 1 in glioblastomas","volume":"68","author":"Mandell","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"23","key":"10.1016\/j.vph.2025.107548_bb0140","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.2235846100","article-title":"A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors","volume":"100","author":"Rubin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.vph.2025.107548_bb0145","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/0008-5472.CAN-09-3642","article-title":"The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects","volume":"70","author":"Hattermann","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.vph.2025.107548_bb0150","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.3390\/ijms22126514","article-title":"Tumor vessels fuel the fire in glioblastoma","volume":"22","author":"Rosi\u0144ska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","article-title":"Vessel co-option and resistance to anti-angiogenic therapy","volume":"23","author":"Kuczynski","year":"2020","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-019-09699-5","article-title":"Introduction to special issue: vascular co-option in cancer","volume":"23","author":"Dudley","year":"2020","journal-title":"Angiogenesis"},{"issue":"6","key":"10.1016\/j.vph.2025.107548_bb0165","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.vph.2025.107548_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5482","key":"10.1016\/j.vph.2025.107548_bb0175","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.289.5482.1197","article-title":"Genes expressed in human tumor endothelium","volume":"289","author":"St Croix","year":"2000","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0180","first-page":"121","article-title":"In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles","volume":"1755","author":"van Beijnum","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.vph.2025.107548_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/onc.2012.49","article-title":"Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1","volume":"32","author":"van Beijnum","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10456-008-9100-x","article-title":"Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration","volume":"11","author":"Legg","year":"2008","journal-title":"Angiogenesis"},{"issue":"2","key":"10.1016\/j.vph.2025.107548_bb0195","first-page":"347","article-title":"Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis","volume":"59","author":"Viti","year":"1999","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.vph.2025.107548_bb0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.vph.2025.107548_bb0205","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.vph.2025.107548_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2424730122","article-title":"Embryonic reprogramming of the tumor vasculature reveals targets for cancer therapy","volume":"122","author":"Huijbers","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.vph.2025.107548_bb0215","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2009-07-232306","article-title":"Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia","volume":"115","author":"Kidoya","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.vph.2025.107548_bb0220","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/brain\/awx253","article-title":"Pharmacological targeting of apelin impairs glioblastoma growth","volume":"140","author":"Harford-Wright","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.vph.2025.107548_bb0225","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.3390\/ijms21114179","article-title":"Apelin controls angiogenesis-dependent glioblastoma growth","volume":"21","author":"Frisch","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2025.107548_bb0230","series-title":"Apelin Signalling: Lineage Marker and Functional Actor of Blood Vessel Formation, Vasculogenesis and Angiogenesis\u2014from Embryonic Development to Regenerative Medicine","author":"Audigier","year":"2011"},{"issue":"8","key":"10.1016\/j.vph.2025.107548_bb0235","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809266","article-title":"Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy","volume":"11","author":"Uribesalgo","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0240","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.advms.2020.02.002","article-title":"Role of Apelin\/APJ axis in cancer development and progression","volume":"65","author":"Masoumi","year":"2020","journal-title":"Adv. Med. Sci."},{"issue":"10","key":"10.1016\/j.vph.2025.107548_bb0245","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1002\/jcp.30845","article-title":"Roles of apelin\/APJ system in cancer: biomarker, predictor, and emerging therapeutic target","volume":"237","author":"Chen","year":"2022","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"10.1016\/j.vph.2025.107548_bb0250","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200616RR","article-title":"Loss of apelin blocks the emergence of sprouting angiogenesis in experimental tumors","volume":"36","author":"Azad","year":"2022","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0255","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1038\/s41598-021-85162-0","article-title":"Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis","volume":"11","author":"Berta","year":"2021","journal-title":"Sci. Rep."},{"issue":"2022","key":"10.1016\/j.vph.2025.107548_bb0260","article-title":"High APLN expression predicts poor prognosis for glioma patients","author":"Lv","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.vph.2025.107548_bb0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ydbio.2007.03.004","article-title":"Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis","volume":"305","author":"K\u00e4lin","year":"2007","journal-title":"Dev. Biol."},{"key":"10.1016\/j.vph.2025.107548_bb0270","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIRCRESAHA.107.158659","article-title":"Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload","volume":"101","author":"Kuba","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2025.107548_bb0275","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518759680","article-title":"Apelin, the devil inside brain tumors","volume":"12","author":"Harford-Wright","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.vph.2025.107548_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1379658","article-title":"Expression of the apelin receptor, a novel potential therapeutic target, and its endogenous ligands in diverse stem cell populations in human glioblastoma","volume":"18","author":"Williams","year":"2024","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0285","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1016\/j.vph.2025.107548_bb0290","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/cancers13153899","article-title":"APLN\/APLNR signaling controls key pathological parameters of glioblastoma","volume":"13","author":"K\u00e4lin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.vph.2025.107548_bb0295","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"issue":"Suppl. 2","key":"10.1016\/j.vph.2025.107548_bb0300","first-page":"001","article-title":"Cancer stem cells: dynamic entities in an ever-evolving paradigm","volume":"7","author":"Lopez-Bertoni","year":"2015","journal-title":"Biol. Med. (Aligarh)"},{"issue":"9","key":"10.1016\/j.vph.2025.107548_bb0305","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-18-0881","article-title":"Targeting APLN\/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA\/VEGFR2 blockade in glioblastoma","volume":"79","author":"Mastrella","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/ph12010045","article-title":"APELA expression in glioma, and its association with patient survival and tumor grade","volume":"12","author":"Ganguly","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.vph.2025.107548_bb0315","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","article-title":"Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy","volume":"13","author":"van Beijnum","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:02:34Z","timestamp":1781208154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189125000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":63,"alternative-id":["S1537189125000874"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107548","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apelin in glioblastoma: A dual target for tumor and vascular intervention","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107548"}}